Cargando…

Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein

Severe acute respiratory syndrome (SARS) is an emerging infectious disease associated with a novel coronavirus and causing worldwide outbreaks. SARS coronavirus (SARS-CoV) is an enveloped RNA virus, which contains several structural proteins. Among these proteins, spike (S) protein is responsible fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Ho, Tin-Yun, Wu, Shih-Lu, Cheng, Shin-Ei, Wei, Yen-Chiao, Huang, Shan-Ping, Hsiang, Chien-Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111049/
https://www.ncbi.nlm.nih.gov/pubmed/14706633
http://dx.doi.org/10.1016/j.bbrc.2003.11.180
_version_ 1783513193395519488
author Ho, Tin-Yun
Wu, Shih-Lu
Cheng, Shin-Ei
Wei, Yen-Chiao
Huang, Shan-Ping
Hsiang, Chien-Yun
author_facet Ho, Tin-Yun
Wu, Shih-Lu
Cheng, Shin-Ei
Wei, Yen-Chiao
Huang, Shan-Ping
Hsiang, Chien-Yun
author_sort Ho, Tin-Yun
collection PubMed
description Severe acute respiratory syndrome (SARS) is an emerging infectious disease associated with a novel coronavirus and causing worldwide outbreaks. SARS coronavirus (SARS-CoV) is an enveloped RNA virus, which contains several structural proteins. Among these proteins, spike (S) protein is responsible for binding to specific cellular receptors and is a major antigenic determinant, which induces neutralizing antibody. In order to analyze the antigenicity and receptor-binding ability of SARS-CoV S protein, we expressed the S protein in Escherichia coli using a pET expression vector. After the isopropyl-β-d-thiogalactoside induction, S protein was expressed in the soluble form and purified by nickel-affinity chromatography to homogeneity. The amount of S protein recovered was 0.2–0.3 mg/100 ml bacterial culture. The S protein was recognized by sera from SARS patients by ELISA and Western blot, which indicated that recombinant S protein retained its antigenicity. By biotinylated ELISA and Western blot using biotin-labeled S protein as the probe, we identified 130-kDa and 140-kDa proteins in Vero cells that might be the cellular receptors responsible for SARS-CoV infection. Taken together, these results suggested that recombinant S protein exhibited the antigenicity and receptor-binding ability, and it could be a good candidate for further developing SARS vaccine and anti-SARS therapy.
format Online
Article
Text
id pubmed-7111049
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-71110492020-04-02 Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein Ho, Tin-Yun Wu, Shih-Lu Cheng, Shin-Ei Wei, Yen-Chiao Huang, Shan-Ping Hsiang, Chien-Yun Biochem Biophys Res Commun Article Severe acute respiratory syndrome (SARS) is an emerging infectious disease associated with a novel coronavirus and causing worldwide outbreaks. SARS coronavirus (SARS-CoV) is an enveloped RNA virus, which contains several structural proteins. Among these proteins, spike (S) protein is responsible for binding to specific cellular receptors and is a major antigenic determinant, which induces neutralizing antibody. In order to analyze the antigenicity and receptor-binding ability of SARS-CoV S protein, we expressed the S protein in Escherichia coli using a pET expression vector. After the isopropyl-β-d-thiogalactoside induction, S protein was expressed in the soluble form and purified by nickel-affinity chromatography to homogeneity. The amount of S protein recovered was 0.2–0.3 mg/100 ml bacterial culture. The S protein was recognized by sera from SARS patients by ELISA and Western blot, which indicated that recombinant S protein retained its antigenicity. By biotinylated ELISA and Western blot using biotin-labeled S protein as the probe, we identified 130-kDa and 140-kDa proteins in Vero cells that might be the cellular receptors responsible for SARS-CoV infection. Taken together, these results suggested that recombinant S protein exhibited the antigenicity and receptor-binding ability, and it could be a good candidate for further developing SARS vaccine and anti-SARS therapy. Published by Elsevier Inc. 2004-01-23 2003-12-29 /pmc/articles/PMC7111049/ /pubmed/14706633 http://dx.doi.org/10.1016/j.bbrc.2003.11.180 Text en Copyright © 2003 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Ho, Tin-Yun
Wu, Shih-Lu
Cheng, Shin-Ei
Wei, Yen-Chiao
Huang, Shan-Ping
Hsiang, Chien-Yun
Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein
title Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein
title_full Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein
title_fullStr Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein
title_full_unstemmed Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein
title_short Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein
title_sort antigenicity and receptor-binding ability of recombinant sars coronavirus spike protein
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111049/
https://www.ncbi.nlm.nih.gov/pubmed/14706633
http://dx.doi.org/10.1016/j.bbrc.2003.11.180
work_keys_str_mv AT hotinyun antigenicityandreceptorbindingabilityofrecombinantsarscoronavirusspikeprotein
AT wushihlu antigenicityandreceptorbindingabilityofrecombinantsarscoronavirusspikeprotein
AT chengshinei antigenicityandreceptorbindingabilityofrecombinantsarscoronavirusspikeprotein
AT weiyenchiao antigenicityandreceptorbindingabilityofrecombinantsarscoronavirusspikeprotein
AT huangshanping antigenicityandreceptorbindingabilityofrecombinantsarscoronavirusspikeprotein
AT hsiangchienyun antigenicityandreceptorbindingabilityofrecombinantsarscoronavirusspikeprotein